Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2015 | short review | Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015

Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2015
Autor:
MD Michael A. Fridrik

Abstract

Double hit (DH) are defined as MYC and BCL2 or/and BCL6 coexpressing B-cell lymphomas. Morphologically they are found in the diffuse large B-cell lymphoma (DLBCL) or in the group of B-cell lymphoma, unclassifiable, with features between DLBCL and Burkitt lymphoma (BCLU). Approximately 5–10 % of DLBCLs and BCLUs are DH lymphomas according to fluorescence in situ hybridization, the percentage rises to 30 %, if protein overexpression is detected by immunohistochemistry. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone seems to be insufficient. However, for more intensive regimens and/or high-dose therapy with stem cell rescue conflicting results exist. Clinical trials with novel therapies are urgently needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe